ReviewWorld journal of gastroenterology2016
Pulmonary complications of hepatic diseases.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Temporal Trends and Demographic Disparities in Respiratory Failure Mortality Among Adults with Chronic Liver Disease: A National Mortality Database Analysis, 1999 to 2024.Diseases (Basel, Switzerland) · 2026Article
- Cardiopulmonary changes and its association with clinical features in noncirrhotic portal hypertension.World journal of gastroenterology · 2025Article
- Incidental Findings in Clinical Practice: A Case of Hepatic Encephalopathy and Subsequent Lung Cancer Detection.Cureus · 2025Article
- The Impact of Hepatic Hydrothorax on the Outcome of Liver Cirrhosis: A Comparative Study.Journal of clinical medicine · 2025Article
- Article
- The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls.Clinical and molecular hepatology · 2022Review
- The importance of liver function assessment before cardiac surgery: A narrative review.Frontiers in surgery · 2022Review
- Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production.Frontiers in immunology · 2021Article
- Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.World journal of gastroenterology · 2020Review
- Portal hypertension in pregnancy - Concealed perils.Obstetric medicine · 2020Article
- Pathologic Intracardiac Bubbles in Patients With Cirrhosis: The Case for an Intestinal Origin.CASE (Philadelphia, Pa.) · 2019Article
- Dyspnea in a Patient with Melanoma.Clinical practice and cases in emergency medicine · 2019Article
- Short-term postoperative outcomes of colorectal cancer among patients with chronic liver disease: a national population-based study.BMJ open · 2018Observational
- Pulmonary Dysfunction in Patients with Cirrhosis of the Liver: A Study of Pulmonary Function Tests and Arterial Blood Gases.International journal of applied & basic medical researchArticle
- Pulmonary Assessment of the Liver Transplant Recipient.Journal of clinical and experimental hepatologyReview
- Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents.Annals of thoracic medicineArticle
- Risk factors for 30-day readmission in adults hospitalized for pulmonary hypertension.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe chronic liver disease (CLD) may result from portal hypertension, hepatocellular failure or the combination of both. Some of these patients may develop pulmonary complications independent from any pulmonary pathology that they may have. Among them the hepatopulmonary syndrome (HPS), portopulmonary hypertension (PPH) and hepatic hydrothorax (HH) are described in detail in this literature review. HPS is encountered in approximately 15% to 30% of the patients and its presence is associated with increase in mortality and also requires liver transplantation in many cases. PPH has been reported among 4%-8% of the patient with CLD who have undergone liver transplantation. The HH is another entity, which has the prevalence rate of 5% to 6% and is associated in the absence of cardiopulmonary disease. These clinical syndromes occur in similar pathophysiologic environments. Most treatment modalities work as temporizing measures. The ultimate treatment of choice is liver transplant. This clinical review provides basic concepts; pathophysiology and clinical presentation that will allow the clinician to better understand these potentially life-threatening complications. This article will review up-to-date information on the pathophysiology, clinical features and the treatment of the pulmonary complications among liver disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.